 Good evening, ladies and gentlemen. What a honor to be here tonight. And what a challenge, three minutes to introduce a research project in plain English, which, by the way, is my second language. I'll try my best. But let me start by saying thank you. Thank you for this great opportunity. And thank you for understanding that new ideas need support in order to progress and became discoveries. But also let me start by asking you a question, which I always ask myself. Can we do something more, something different, to help glioblastoma patients? I'm a scientist, so what I do is to ask questions in order to find new answers. So how is it possible that over the last 20 years, there has been no progress in the survival or treatment for glioblastoma patients? Most drugs try to directly kill tumor cells. And very often they are associated with dramatic side effects for the patient. Maybe we should do something different. What if we try to make our own body and more precisely our immune system able to fight the tumor? Here is the good news. We know that the immune system is able to fight the tumor. The bad news is that the tumor can block it. And that's why we need to make it stronger. And that's what we do with immune therapies. So in order to help our immune system, we have been developing a way to deliver a potent immune stimulator directly to the tumor. We knew that some of our blood cells are actually attracted to the tumor. So we decided to use them as a cellular vehicle to deliver the potent immune stimulator to the tumor. Using genetic engineering technology, we can reprogram these cells to produce the immune stimulator. And we can give them precise instructions to release it only after they reach the tumor. So we can avoid systemic toxicity. At the same time, we have been developing a tumor vaccine, which helps the immune system to localize and recognize the tumor cells. So in summary, on one side, we're making our immune system stronger, more active. And on the other side, we are making the tumor cells more visible. So together, this should help the immune system find, attack, and eliminate the tumor. We have preliminary, but very promising data suggesting that this strategy may work for glioblastoma. And with your gift, we will be able to progress this research with the very final goal of moving it into the clinic to treat patients. So let me end my talk the way I began it and ask you the same question. Can we do something more to help glioblastoma patients? With your help together, I think we will. Thank you very much for your support.